Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.
Zhang Q, Basappa J, Wang HY, Nunez-Cruz S, Lobello C, Wang S, Liu X, Chekol S, Guo L, Ziober A, Nejati R, Shestov A, Feldman M, Glickson JD, Turner SD, Blair IA, Van Dang C, Wasik MA. Zhang Q, et al. Among authors: nunez cruz s. Leukemia. 2023 Dec;37(12):2436-2447. doi: 10.1038/s41375-023-02038-0. Epub 2023 Sep 29. Leukemia. 2023. PMID: 37773266
Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.
Zhang Q, Wang HY, Nayak A, Nunez-Cruz S, Slupianek A, Liu X, Basappa J, Fan JS, Chekol S, Nejati R, Bogusz AM, Turner SD, Swaminathan K, Wasik MA. Zhang Q, et al. Among authors: nunez cruz s. Am J Pathol. 2022 Aug;192(8):1186-1198. doi: 10.1016/j.ajpath.2022.05.005. Epub 2022 May 28. Am J Pathol. 2022. PMID: 35640677 Free PMC article.
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA. Ruella M, et al. Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27. Clin Cancer Res. 2016. PMID: 26819453
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4.
Bhoj VG, Li L, Parvathaneni K, Zhang Z, Kacir S, Arhontoulis D, Zhou K, McGettigan-Croce B, Nunez-Cruz S, Gulendran G, Boesteanu AC, Johnson L, Feldman MD, Radaelli E, Mansfield K, Nasrallah M, Goydel RS, Peng H, Rader C, Milone MC, Siegel DL. Bhoj VG, et al. Among authors: nunez cruz s. Mol Ther Oncolytics. 2021 Jan 26;20:387-398. doi: 10.1016/j.omto.2021.01.012. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33614919 Free PMC article.
CD38 as a pan-hematologic target for chimeric antigen receptor T cells.
Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, June CH, Teachey DT, Tasian SK, Aplenc R, Gill S. Glisovic-Aplenc T, et al. Among authors: nunez cruz s. Blood Adv. 2023 Aug 22;7(16):4418-4430. doi: 10.1182/bloodadvances.2022007059. Blood Adv. 2023. PMID: 37171449 Free PMC article.
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.
Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, Bennett P, Barton N, Wu Q, Zhang J, Wang Y, Wei L, Cogan S, Ezell T, Joshi S, Latimer KJ, Granda B, Tschantz WR, Young RM, Huet HA, Richardson CJ, Milone MC. Bu DX, et al. Oncotarget. 2018 May 25;9(40):25764-25780. doi: 10.18632/oncotarget.25359. eCollection 2018 May 25. Oncotarget. 2018. PMID: 29899820 Free PMC article.
32 results